Atossa Therapeutics, Inc. (ATOS) stock
ATOSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.90−0.03 (-1.55%)
Close on Nov 17, 2026Market cap $18.96MP/E –Yield –
Earnings
Atossa Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Jan 8, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.56
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Atossa Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Jan 8, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 10, 2026before the open | – | – | -$0.56 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 7, 2026before the open | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Jan 9, 2026before the open | – | – | – | Filing |
| Q3 FY2025ended Sep 30, 2025 | Nov 12, 2025before the open | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 12, 2025before the open | – | – | -$0.07 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 13, 2025before the open | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 25, 2025before the open | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024before the open | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 12, 2024before the open | – | – | -$0.05 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 13, 2024before the open | – | – | -$0.05 | Release |
| Q4 FY2023ended Dec 31, 2023 | Apr 1, 2024after the close | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 13, 2023before the open | – | – | -$0.05 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 14, 2023before the open | – | – | -$0.08 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 15, 2023before the open | – | – | -$0.05 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 22, 2023after the close | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 7, 2022after the close | – | – | -$0.06 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 8, 2022after the close | – | – | -$0.05 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 9, 2022after the close | – | – | -$0.04 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 28, 2022after the close | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 15, 2021before the open | – | – | -$0.04 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 13, 2021during market hours | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 14, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 31, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 13, 2020during market hours | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 13, 2020during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Atossa Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Atossa Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Atossa Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- Update
- Results
- Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 OutlookUpdate
- News
- News
- Results
- Update
- News
- Results
- Results
- Results
- News
See a number that looks wrong?